TLX 2.78% $19.93 telix pharmaceuticals limited

Radiopharm - anyone know how this compares to TLX?

  1. 197 Posts.
    lightbulb Created with Sketch. 24

    RADIOPHARM THERANOSTICS CLOSES A$152M ASX IPO HEAVILY OVERSUBSCRIBED

    • Radiopharm Theranostics is focused on development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs
    • Highly prospective portfolio of four distinct & clearly differentiated platform technologies
    • Pipeline candidate selection based on their potential to be First to Market or Best in Class in the respective therapeutic applications
    • Deep clinical pipeline of five Phase 2 trials and two Phase 1 trials ongoing, with a total of 133 patients dosed to date
    • Key executives secured including former AAA/Novartis CCO Riccardo Canevari as CEO & MD, Prof David Mozley as CMO and Dr Thom Tulip as CTO
    • Radiopharm raised A$50m as part of the IPO, listing with a market capitalisation of A$152m under the code RAD
    • The IPO closed heavily oversubscribed, with strong support from a range of institutional, sophisticated and retail investors both locally and overseas
    • Expected to list on the ASX Thursday 25 November 2021
    • Founded by Australian biotech entrepreneur Paul Hopper, who will have a 35.53% shareholding upon listing
    • Bell Potter and Baker Young are Joint Lead Managers to the IPO


 
watchlist Created with Sketch. Add TLX (ASX) to my watchlist
(20min delay)
Last
$19.93
Change
0.540(2.78%)
Mkt cap ! $6.669B
Open High Low Value Volume
$19.49 $20.00 $18.97 $53.42M 2.706M

Buyers (Bids)

No. Vol. Price($)
1 601 $19.92
 

Sellers (Offers)

Price($) Vol. No.
$19.93 2099 2
View Market Depth
Last trade - 16.10pm 12/07/2024 (20 minute delay) ?
TLX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.